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Abstract
The main objective of asthma treatment is to control symptoms of the disease; however, despite the availability of guidelines and 
many groups of medications, the degree of control of this condition is insufficient. In difficult-to-treat asthma, the optimal control 
cannot be achieved due to reasons independent of the disease. Factors worsening asthma control include: inadequate treatment 
plan (low therapy adherence and compliance), inappropriate inhalation technique, insufficient symptom control using the available 
classes of medications, incomplete response to treatment (non-responders, steroid-resistance), incorrect diagnosis of asthma or 
comorbidities, and environmental factors. In order to achieve the optimal asthma control, it is recommended to: take therapeutic 
decisions with the patient, assess the probability of non-compliance, perform detailed diagnostics and initiate treatment of conco-
mitant diseases, carry out differential diagnosis of conditions mimicking asthma, educate the patient as to the inhalation technique 
and check it, eliminate unfavourable environmental factors, and modify current treatment. New treatment options for patients with 
asthma include: ultra-long-acting beta2-agonists, long-acting muscarine receptor antagonists (LAMA), monoclonal antibodies, 
and non-pharmacological interventions. The only LAMA approved for treatment of asthma is tiotropium bromide. The analyses 
performed demonstrated a high efficacy of tiotropium in terms of improved lung function parameters and prolonged time to the 
first asthma exacerbation. It is recommended as an add-on therapy at asthma treatment steps 4 and 5 according to GINA (Global 
Initiative for Asthma) 2014. The optimal asthma control is important from the medical as well as the economical point of view. 
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Definition
Asthma is a chronic inflammatory disease 
of the lower airways, characterised by episodes 
of dyspnoea, cough, and chest discomfort. The 
main objective of asthma treatment is to control 
symptoms, prevent exacerbations, and inhibit 
deterioration of lung function, while mainta-
ining the optimal safety profile of the applied 
interventions. Despite guidelines developed and 
continuously improved by expert groups, the 
degree of asthma control remains insufficient in 
many countries [1].
Difficult-to-treat asthma is defined as asth-
ma in which control cannot be achieved due to 
reasons independent of the disease (such as co-
morbidities, exposure to environmental factors, 
or non-compliance) [2]. 
Severe asthma is diagnosed when the optimal 
symptom control has not been achieved despite 
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compliance, the use of high-doses of ICS in com-
bination with other agents, and adequate control 
or the lack of concomitant diseases. This category 
includes also patients in whom an attempt to 
introduce less aggressive treatment results in 
worsening of asthma control [2].
In order to define precisely the subgroups 
of patients with different reactions to treatment, 
the following terms must be distinguished: severe 
asthma, uncontrolled asthma, difficult-to-treat 
asthma, and refractory asthma. 
According to the ATS/ERS criteria, severe 
asthma is defined as follows [3, 4]:
—  in order to prevent asthma from being uncon-
trolled, GINA step 4 or 5 treatment (i.e. hi-
gh-dose inhaled glucocorticosteroids [ICS] 
and long-acting beta-2-agonists [LABA] + other 
controllers) has been required in the previous 
year, or systemic glucocorticosteroids have been 
used in more than 50% of days of the year, or 
— despite such treatment, the optimal control 
has not been achieved.
Epidemiology of uncontrolled asthma
The available epidemiological data suggest 
that in about 5–10% of adult patients, the optimal 
asthma control is not achieved, even if GINA 2015 
step 4 or 5 treatment is applied [5]. Asthma con-
trol according to GINA is difficult to estimate as 
it is based on the patient’s subjective assessment, 
affected by gradual adaptation to symptoms, in-
creasing with time and clinical progression of the 
disease. In an international study evaluating the 
degree of asthma control in Central and Eastern 
Europe (Asthma Insights & Reality in Central and 
Eastern Europe — AIRCEE), a group of 300 Polish 
patients with asthma was investigated [6]. More 
than 70% of respondents reported the occurrence 
of asthma symptoms at least once a week, and in 
20% symptoms were present on every day. In the 
investigated group, 45% of patients complained of 
symptoms at night, of whom in 11% the symptoms 
were present every night. More than 50% of pa-
tients required the use of on-demand bronchodila-
tors. Only 27% of patients with asthma used ICS. 
In the investigated group, 18% of adult patients 
and 8% of children were hospitalized, and nearly 
half of the patients had required emergency room 
treatment due to asthma in the previous year.
Asthma control criteria
According to the criteria proposed by ERS/ATS 
[3, 4], asthma is uncontrolled when at least one 
of the following is true , despite GINA step 4 or 5 
treatment or systemic CS for more than half of 
the previous year:
—  insufficient symptom control, i.e. the Asthma 
Control Questionnaire score consistently over 
1.5, or the Asthma Control Test score below 20;
—  frequent severe exacerbations, i.e.  two or 
more episodes requiring systemic glucocor-
ticosteroids (lasting more than 3 days) in the 
previous year;
—  serious exacerbations, i.e. at least one ho-
spitalization, stay at an intensive care unit, 
or mechanical ventilation in the previous 
year;
—  airflow limitation, i.e. post-bronchodilator 
FEV1 below 80% of the predicted value;
—  controlled asthma that worsens on tapering 
of high doses of ICS or systemic glucocorti-
costeroids.
Experts’ recommendation
The degree of asthma control should be 
assessed in two domains, i.e. current symptom 
control and the risk of future events (exacerba-
tions, deterioration of lung function, or respi-
ratory disability). Airflow limitation should be 
monitored by means of assessment of lung func-
tion: before treatment initiation or modification, 
after 3–6 months, and periodically during the 
treatment (at least once a year).
Asthma severity should be first assessed 
after several months of treatment. According to 
GINA 2014, uncontrolled asthma should be dia-
gnosed when at least 3 of the following criteria 
are met [2]: symptoms of the disease are present 
more than twice a  week; nocturnal awaking 
occurs; rescue inhalers (apart from preventive 
application before exercise) are used more than 
twice a week; limitation of everyday activities 
is present.
If the optimal asthma control has not been 
achieved, the following actions should be under-
taken in parallel:
—  correctness of the inhalation technique should 
be checked and the patient should be adequ-
ately trained or the method of application of 
inhaled medications should be changed;
—  differential diagnostics of conditions with 
a clinical picture that may be similar to that 
of asthma should be carried out;
—  the diagnosis of asthma should be confirmed;
—  concomitant diseases should be effectively 
treated;
—  unfavorable environmental factors should be 
eliminated, if possible;
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—  the treatment plan should be adjusted to 
the patient’s needs, any doubts should be 
discussed, and further treatment should be 
planned with the patient;
—  introduction of additional medications or 
stepping-up of treatment (according to GINA 
2015) should be considered.
Diagnosing and monitoring of factors affecting 
asthma control
The most important factors impairing asthma 
control include:
—  low therapy adherence and compliance 
(i.e. inadequate treatment plan) [7, 8],
—  incorrect inhalation technique [8],
—  insufficient symptom control using the ava-
ilable classes of medications [9, 10],
—  incomplete response to treatment (non-re-
sponders, steroid-resistance),
—  incorrect diagnosis of asthma or comorbidities,
—  environmental factors [11, 12].
In case of asthma treatment failure, the 
authors recommend an algorithm presented on 
Figure 1. 
Low patient’s compliance and adherence  
to treatment
One problem impairing achievement of the 
optimal asthma control is patient non-com-
pliance. The term “compliance” refers to the 
degree to which a patient correctly follows me-
dical advice. At present, a wider term “adhe-
rence” is used more commonly; this includes 
and stresses the patient’s active participation 
in treatment planning and implementation of 
the developed treatment plan. It is estimated 
that about 50% of adults and children receiving 
long-term treatment due to asthma do not use 
their medication in the correct manner [13]. 
What is important, this happens more often in 
patients with difficult-to-treat asthma than in 
patients with well-controlled asthma, and there-
Figure 1. Recommended management of patients with suboptimal asthma control
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fore achievement of satisfactory treatment effects 
is extremely difficult. Apparently, in everyday 
practice this may be one of the main reasons for 
the lack of optimal asthma control. In a British 
study, 35% of patients with asthma prescribed 
with inhaled combination treatment complied 
with the medical advice in less than 50% [14]. In 
another study, 65% of patients using ICS and 60% 
of those using long-acting b2-agonists complied 
with the medical advice in less than 80% [15]. 
Low-adherence patients had significantly worse 
lung function parameters (post-bronchodilator 
FEV1 75.4 vs. 84.3, p < 0.05), higher probability 
of ventilation disorders due to asthma (19.2% vs. 
2.6%, p = 0.02), and higher sputum eosinophil 
counts (0.66% vs. 0.54%, p = 0.05) [16].
Reasons for insufficient treatment adherence 
include [2]:
1. Treatment regimen (difficulties using the 
inhaler; multiple inhalations per day; use of 
several different inhalers).
2. Unintentional factors (misunderstanding 
of the instructions; forgetfulness; absence 
of a daily routine; treatment cost).
3. Intentional factors (perception that treatment 
is not necessary; denial or anger about asthma 
or its treatment; inappropriate expectations; 
concerns about adverse effects (mainly stero-
idophobia); dissatisfaction with health care 
providers; stigmatization; cultural or religious 
issues; treatment cost).
In assessment and improvement of adhe-
rence, the skill of appropriate conversation with 
asthma patients is important. Asking the right 
questions is an important issue; for example [17]: 
“Many patients do not use their inhaler as prescri-
bed. In the last month, how many days per week 
have you used your prescribed inhalers — not 
at all, once, twice, three times, or more?” or “Do 
you find it easier to remember to use your inhaler 
in the morning or in the evening?” In Poland, it 
is also possible to check the date of the last pre-
scription of inhalers for a specific patient and the 
date and dose counter on the inhaler.
Experts’ recommendation
In order to achieve the optimal adheren-
ce, it is recommended to take the decision on 
selection of the optimal treatment option with 
the patient [18]. Modification of ICS dosing is 
worth considering (according to study results, 
one dose per day instead of two improves 
adherence[19]). During follow-up visits, the 
probability of non-adherence should be asses-
sed, and the patient should be encouraged to 
discuss optimization of the applied treatment.
Comorbidities and diseases with clinical 
picture similar to that of asthma 
One reason for poor asthma control is ina-
dequate treatment or the lack of treatment of 
concomitant diseases. Comorbidities are reco-
gnized as a factor increasing the risk of asthma 
exacerbations [20]. In patients with asthma, con-
ditions such as gastroesophageal reflux, obesity, 
obstructive sleep apnoea, or chronic rhinitis and 
sinusitis are common and require diagnostics 
and specialist treatment. Psychological problems 
that should be consulted with a psychologist or 
a psychiatrist are also quite common. 
If asthma control is difficult to achieve, diffe-
rential diagnostics of conditions with symptoms 
that may be similar to those of asthma should be 
intensified. According to data, in 12–30% of ca-
ses “uncontrolled asthma” was actually another, 
misdiagnosed condition [21, 22]. The most com-
mon conditions that may be mistaken for asthma 
and their differential diagnosis are presented in 
Table 1.
Experts’ recommendation
If asthma control is difficult to achieve, 
detailed differential diagnostics of conditions 
with symptoms that may be similar to those of 
asthma and/or concomitant diseases impairing 
achievement of the optimal asthma control 
should be performed. 
Incorrect inhalation technique
Incorrect inhalation technique is a  factor 
impairing achievement of the optimal asthma 
control as it increases the risk of both disease 
exacerbations and the adverse effects of treat-
ment [23]. It is estimated that most patients (up 
to 70–80%) use their inhalers in an incorrect 
manner and are not aware of the errors they 
make. In a French survey study, 3955 patients 
with asthma using ICS delivered via a pressuri-
zed metered dose inhaler took part [24]. 
Incorrect use of the inhaler was observed in 
71% of the participants, of whom 47% used it 
incorrectly due to poor coordination between 
inspiration and dose release. In the same group, 
78% of the respondents made more than 1 error 
or omission during an inhalation. Despite that, 
only 15% of patients who used their inhalers 
incorrectly and 23% of those with poor coor-
dination reported their inhalation technique 
as poor or very poor. It is worth stressing that 
some physicians are not able to demonstrate 
the correct method of use of the inhaler they 
prescribe to the patient [25]. 
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Table 1. Asthma differential diagnoses in adult patients
Disease Diagnostics
Vocal cord dysfunction Laryngoscopy/plethysmography
Diseases of the paranasal sinuses Computed tomography, endoscopy
Obstructive sleep apnoea Polysomnography
COPD Thorough medical history, spirometry
Bronchiolitis obliterans Plethysmography/HRCT/biopsy with histopathological examination
Hyperventilation in anxiety episodes Consultation by a psychiatrist
Interstitial lung diseases Lung diffusion capacity test/chest HRCT
Bronchiectases Chest HRCT
Emphysema Lung diffusion capacity test/chest HRCT
Pulmonary embolism Chest angio-CT
Foreign body in the airways (aspiration, tumour, others) Bronchoscopy
Gastrooesophageal reflux disease (GERD) Gastroscopy/pH-metry
Churg-Strauss Syndrome Biopsy with histopathological examination, ANCA
Cystic fibrosis Sweat test
Adverse effects of angiotensin converting enzyme inhibitors Medical history
Congestive heart failure Echocardiography/BNP
Allergic bronchopulmonary aspergillosis Chest HRCT, sputum examination for mould filaments, skin tests, cIgE, 
sIgE, precipitins
Sarcoidosis Imaging tests, biopsy with histopathological examination
Pulmonary hypertension Angio-CT of pulmonary arteries, vessel catheterization, heart ultrasound
Education is a  factor that may significan-
tly improve the patients’ inhalation technique. 
Guidance as to the use of the inhaler was provided 
to 84% of the respondents, and in 68% of them 
correctness of the inhalation technique was chec-
ked and possible errors corrected [264]. The pa-
tients who received training in both aspects men-
tioned above made significantly less errors using 
their inhalers (66.5% vs. 86.4%; p < 0.0001). The 
patients who received no instructions were more 
likely to report due to exacerbation of asthma 
symptoms than those trained by the physician 
(3.3% vs. 6.2%; p = 0.005). A slight but statisti-
cally significant decrease of the peak expiratory 
flow rate was also noted in patients who were 
not instructed as to the inhalation technique in 
comparison with patients who received such 
instructions (70.4 ± 0.4 vs. 72.9 ± 1.0; p = 0.02).
Experts’ recommendation
When prescribing inhaled medications for 
the first time, it is recommended to instruct 
the patient as to the use of the inhaler and 
the inhalation technique, and to check cor-
rectness of the inhalation technique during 
follow-up visits. The first step is selection of 
the appropriate inhaler type. The availability 
of specific types, their price, and the convenien-
ce of application should be taken into account. 
It is recommended that the patient should take 
part in decision-making for the method of ad-
ministration of inhaled medications. In the case 
of pressurized metered dose inhalers, the use 
of a spacer improves deposition of drug partic-
les and reduces the risk of adverse effects (for 
ICS — oral candidiasis, dysphonia). It is also 
important to determine whether any conditions 
or physical barriers potentially affecting the 
process of inhalation are present. If multiple 
inhaled medications are prescribed, it is be-
neficial to prescribe them in the same inhaler. 
If the patient has problems to learn an effective 
inhalation technique, an alternative method of 
administration of inhaled medications may be 
considered. It is recommended to avoid frequ-
ent changes of the inhaler type and the use of 
multiple different inhalers in the same patient.
New treatment options
Limited efficacy of medications currently 
used in the treatment of severe asthma makes 
it necessary to look for new treatment options. 
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Table 2. Add-on therapies in the non-controlled asthma treatment according to GINA 2014 and ERS/ATS, modified
Group Type Efficacy
Without phenotyping Tiotropium Recently approved for treatment of asthma in the European Union. Efficacy in 
lung function improvement, symptom reduction, and control of disease exacer-
bations
Theophylline No effect on the number of asthma exacerbations despite improved results of 
lung function tests
LTRA Efficacy in lung function improvement and control of disease exacerbations; 
less common adverse effects in comparison with LABA but worse compliance
Low doses of oral glucocortico-
steroids
Benefits and risks associated with adverse effects must be thoroughly conside-
red in each case
With phenotyping Anti-IgE therapy (omalizumab) ICS dose reduction and decreased frequency of asthma exacerbations with an 
acceptable safety profile
Sputum-based ICS dose optimi-
sation
Effective in reduction of frequency of asthma exacerbations in selected pa-
tients
Anti-IL-5 therapy (mepolizumab) Improved asthma control, reduction of exacerbations
Anti-IL-13 therapy (lebrikizumab) Improvement of lung function parameters, reduction of frequency of asthma 
exacerbations. Phase 2 of clinical trials has recently been completed.
Anti-IL-4 and anti-IL-13 therapy 
(dupilumab)
Reduction of frequency of exacerbations in moderate to severe asthma
CXCR2 antagonists Currently in the stage of initial trials
Non-pharmacological 
interventions
Bronchial thermoplasty Efficacy in certain patient groups. No data on long-term effects
At present, new classes of medications, including 
ultra-long-acting beta2-agonists (uLABA) and lon-
g-acting muscarine receptor antagonists (LAMA) 
are being intensively investigated.
Long-acting muscarine receptor antagonists 
(LAMA) constitute a group of bronchodilators 
with a mechanism of action different from that of 
LABA. These are anticholinergic agents, mainly 
antagonists of the M3 receptor present in bron-
chial smooth muscles, that act to relax them. This 
group includes such compounds as tiotropium, 
aclidinium, umeclidinium, and glycopyrronium. 
At present, the only marketed agent in this group 
registered for asthma treatment is tiotropium 
bromide. This agent will be discussed in more 
detail below in this review.
Apparently, in order to improve compliance, 
future treatment of moderate to severe asthma 
will be based on combination products containing 
two or three medications (ICS, uLABA, and/or 
LAMA) in one inhaler.
New biological treatments (other than oma-
lizumab) are not discussed in detail as their 
efficacy and safety profiles are being investiga-
ted. The only agent in this group registered for 
asthma treatment is omalizumab — an anti-IgE 
antibody. GINA 2014 guidelines recommend its 
use in patients with moderate to severe asthma 
in whom the optimal asthma control cannot be 
achieved using step  4 treatment [2]. In most 
cases, it is well tolerated; adverse effects typical 
for biologic treatments (including anaphylactic 
reactions) may occur sporadically. A disadvantage 
of biologic therapies is a high treatment cost. The 
incremental cost-effectiveness ratio for omalizu-
mab is GBP 83,822 per quality-adjusted life year 
(QALY) in adults and adolescents [27]. 
New add-on treatment options are summa-
rized in Table 2.
Another option is the use of uLABA. Their 
mechanism of action is the same as that of co-
nventional LABA. The activity of the currently 
used LABA (i.e. salmeterol and formoterol) lasts 
12 hours which makes it necessary to use them in 
at least 2 daily doses. New uLABA remain active 
for more than 24 hours. This group includes olo-
daterol, indacaterol, and vilanterol. Indacaterol 
is an uLABA registered for use in treatment of 
patients with COPD in the USA and Europe. The 
results of a randomised, double-blind clinical trial 
demonstrated that indacaterol in combination 
with mometasone furoate was at least as effica-
cious as mometasone with respect to the time to 
the first serious asthma exacerbation (0.3% vs. 
0.8%; p = 0.16) [28]. A combination of indacaterol 
and mometasone was superior to mometasone 
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alone with respect to the total number of asthma 
exacerbations requiring oral glucocorticosteroids 
per year (rate ratio: 0.71; 95% CI: 0.55 to 0.90; 
p = 0.005). The number of patients in whom 
adverse effects occurred was similar in both gro-
ups. Vilanterol is available in combination with 
fluticasone furoate and has been registered by the 
European Medicines Agency (EMA) for treatment 
of both COPD and asthma. The use of this pro-
duct in the diseases mentioned above is justified 
by the results of randomised clinical trials that 
demonstrated the efficacy of vilanterol in patients 
with asthma [29]. In a randomised clinical trial, 
the participants (n = 2020) were assigned to one 
of two groups [30]. In one group, the patients 
received one dose of vilanterol (22 mcg) in combi-
nation with fluticasone (92 mcg), and in the other 
— one daily dose of fluticasone (92 mcg). The 
patients receiving vilanterol gained additional 
benefit from treatment in comparison with those 
receiving ICS only — a significant reduction of 
the probability of a severe asthma exacerbation 
in 52 weeks (from 15.9% to 12.8%; p = 0.036) 
was demonstrated. A study by Woodcock et al. in 
a large group of patients (n = 806) demonstrated 
no statistically significant differences with respect 
to most endpoints concerning lung function tests 
between patients receiving fluticasone furoate 
(92 mcg) and vilanterol (22 mcg) in a single da-
ily dose and those using fluticasone propionate 
(250 mcg) and salmeterol (50 mcg) twice daily 
[31]. In a post hoc analysis, a significant impro-
vement of the quality of life measured using the 
AQLQ+12 questionnaire (scores higher by ≥ 0.5) 
in favour of the combination of fluticasone furoate 
and vilanterol (OR = 1.39 [1.02; 1.89]).
Role of tiotropium in asthma control
Tiotropium bromide is a muscarine receptor 
antagonist, i.e. an anticholinergic agent. Altho-
ugh it is not selective for specific subtypes of the 
muscarine receptor, after topical application it 
acts mainly as an antagonist of the M3 receptor, 
present on smooth muscle cells and the cells of 
submucosal glands [32]. Its activity results in 
smooth muscle relaxation and decreased mucus 
production, and eventually in bronchodilation. 
Tiotropium remains active for more than 24 hours 
and therefore may be applied in a single daily 
dose [33].
So far, tiotropium delivered by the Handi-
Haler® or Respimat® inhaler, has been registered 
for use in treatment of COPD, in which numero-
us clinical trials made it possible to investigate 
thoroughly the activity and safety profile of this 
agent. The analyses demonstrated a significant 
effect of tiotropium on lung function parameters 
and subjective reduction of dyspnoea in patients 
with COPD [34, 35].
In the search of new treatment options for 
patients with asthma (for whom, except an an-
ti-IgE monoclonal antibody, no new groups of 
medications have been registered for more than 
10 years), investigators focused on long-acting 
anticholinergic agents, including tiotropium. In 
the TALC (Tiotropium Bromide as an Alternative 
to Increased Inhaled Corticosteroid in Patients 
Inadequately Controlled on a Lower Dose of In-
haled Corticosteroid) study, the efficacy of tiotro-
pium added to ICS in patients with uncontrolled 
asthma receiving ICS alone was evaluated [36]. 
One tested hypothesis was that in patients with 
asthma suboptimally controlled with ICS alone, 
the addition of tiotropium bromide would be more 
beneficial than doubling the dose of ICS. Another 
hypothesis was that in such patients the addition 
of tiotropium would be no less efficacious than 
the addition of a LABA. The study inclusion cri-
teria were: age over 18 years, a history of asthma 
confirmed by bronchial obstruction reversibility 
test or bronchial hyper-reactivity, FEV1 higher 
than 40%, and non-smoking status (less than 
10 pack years). The primary endpoint was PEF 
measured in the morning. Secondary endpoints 
included: pre-bronchodilator FEV1, the number of 
days with optimal asthma control (defined as days 
without symptoms, on which the use of emergen-
cy bronchodilators was not necessary), symptoms 
of the disease, the use of emergency bronchodila-
tors, asthma exacerbations (defined as increased 
severity of asthma symptoms requiring the use 
of oral glucocorticosteroids, or increased dose of 
ICS or other asthma medications), the utilisation 
of healthcare services, respiratory inflammation 
markers, and validated questionnaires concerning 
the course and treatment of asthma (Asthma Con-
trol Questionnaire, Asthma Symptom Utility In-
dex, Asthma Quality-of-Life Questionnaire). Two 
hundred and ten patients with moderate chronic 
asthma in whom disease control was not achieved 
with inhaled beclomethasone (80 mcg twice daily) 
were randomized into three groups: addition of 
tiotropium (18 mcg) to beclomethasone, along 
with a  salmeterol inhaler containing placebo; 
doubled dose of beclomethasone (160 mcg) in 
two daily doses with addition of a  salmeterol 
inhaler containing placebo and a tiotropium in-
haler containing placebo; addition of salmeterol 
(50 mcg twice daily) to beclomethasone, along 
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with a tiotropium inhaler containing placebo. In 
patients receiving tiotropium, the morning PEF 
was significantly higher (by 25.8  litres per mi-
nute) than in patients receiving a double dose of 
the ICS (95% CI: 14.4 to 27.1; p < 0.001). Similar 
results were obtained for the comparison of pa-
tients receiving tiotropium with those receiving 
the doubled dose of ICS with respect to evening 
PEF values (a difference of 35.5 litres in favour 
of tiotropium; 95% CI: 24.6 to 46.0; p < 0.001), 
pre-bronchodilator FEV1 (a difference of 0.1 litres 
in favour of tiotropium; 95% CI: 0.03 to 0.17; 
p = 0.0004), the proportion of days with optimal 
asthma control (a difference of 0.079 in favour of 
tiotropium; 95% CI: 0.019 to 0.14; p = 0.01), as-
sessment of daily asthma symptoms (a difference 
of −0.11 in favour of tiotropium; 95% CI: −0.16 
to −0.06; p < 0.001), the Asthma Control Qu-
estionnaire score (a difference of −0.18 in favour 
of tiotropium; 95% CI: −0.34 to −0.03; p = 0.02), 
and FEV1 after 4 inhaled doses of albuterol (a dif-
ference of −0.04 liter in favour of tiotropium; 
95% CI: 0.01 to 0.008; p = 0.01). In comparison 
with patients receiving salmeterol, no differences 
were found in patients using tiotropium with 
respect to morning or evening PEF values, the 
proportion of days with optimal asthma control, 
assessment of daily asthma symptoms, or the 
Asthma Control Questionnaire score. Greater be-
nefits from addition of tiotropium in comparison 
with salmeterol as an add-on to ICS therapy were 
observed with respect to pre-bronchodilator FEV1 
(a difference of 0.11 liter in favor of tiotropium; 
95% CI: 0.04 to 0.18; p = 0.003) and FEV1 after 
4 inhaled doses of albuterol (an increase of 0.07 
liter in favour of tiotropium; 95% CI: 0.05 to 
0.010; p < 0.001).
In two randomized clinical trials, 912 pa-
tients with severe asthma were analyzed. They 
were randomized to two groups: in one, tiotro-
pium 5 mcg delivered via the Respimat inhaler 
was added to the background therapy; in the 
other, the patients received placebo [37]. Enrolled 
patients were those with severe asthma in whom 
the disease remained uncontrolled despite treat-
ment with ICS and LABA, with objective signs 
of chronic obstruction (post-bronchodilator FEV1 
≤ 80%). In week 24, in patients receiving tiotro-
pium a significant improvement of the FEV1 valu-
es in 24-hour monitoring and of the mean weekly 
morning PEF values were observed. Addition of 
tiotropium significantly prolonged the time to the 
first severe exacerbation by 56 days in comparison 
with the placebo group (an improvement by 31%) 
and reduced the risk of exacerbation by 21% in 
comparison with the control group (relative risk 
0.79; p = 0.03). The effect of added tiotropium 
on the time to subsequent exacerbations was not 
investigated. In addition, tiotropium was found to 
have a favorable safety profile – its addition was 
not associated with more adverse effects than in 
the placebo group. 
An analysis of ACQ-7 (Asthma Control Qu-
estionnaire) forms from 6 phase III randomized 
clinical trials in patients with symptomatic 
asthma demonstrated a significant improvement 
with respect to asthma symptom reduction follo-
wing addition of tiotropium bromide to standard 
treatment (i.e.  at least ICS) [38]. The analysis 
included: two 48-week clinical trials (PrimoTi-
nA — addition of tiotropium 5 mcg to ICS), two 
24-week clinical trials (MezzoTinA — addition 
of tiotropium 5/2.5 mcg to ICS), a 12-week cli-
nical trial (GraziaTinA — addition of tiotropium 
5/2.5 mcg to ICS), and a 52-week clinical trial 
(Study 464 — addition of tiotropium 5/2.5 mcg 
to ICS). The respective mean basic ACQ-7 scores 
were: PrimoTinA 2.63 (SD 0.69); MezzoTinA 2.18 
(SD 0.49); GraziaTinA 2.10 (SD 0.42); Study 464 
1.95 (SD 0.39). The mean difference with respect 
to response in favor of tiotropium for specific 
studies was: PrimoTinA, 5 mcg −0.132 ± 0.049 
(p = 0.007); MezzoTinA, 5 mcg −0.115 ± 0.043 
(p = 0.008), 2.5 mcg −0.160 ± 0.043 (p < 0.001); 
GraziaTinA, 5 mcg 0.014 ± 0.067 (p = 0.835), 
2.5 mcg 0.061 ± 0.067 (p = 0.362). The mean 
ACQ-7 score in the Study 464 was 0.98 (SD 0.63), 
1.09 (SD 0.72), and 0.99 (SD 0.68) for 5 mcg, 
2.5 mcg, and placebo, respectively. The study 
demonstrated that the addition of tiotropium 
bromide in a single daily dose to ICS therapy was 
associated with improved asthma control.
An advantage of tiotropium is its convenient 
dosing — the administration of one daily dose 
of 5 mcg makes it possible to achieve the same 
lung function parameters as with two doses of 
2.5 mcg [33].
The asthma/COPD overlap syndrome (ACOS) 
in which asthma coexists with chronic obstruc-
tive pulmonary disease (COPD) is commonly 
encountered in clinical practice. The definitions, 
diagnostic methods, and potential practical im-
portance of the diagnosis of ACOS require further 
research and discussion. In general practice, it is 
sometimes difficult to establish an unequivocal 
diagnosis, and addition of tiotropium is beneficial 
in both conditions. Magnussen et al. published 
the results of a randomized clinical trial evalu-
ating the efficacy of addition of tiotropium to 
standard treatment in patients suffering from both 
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Table 3. The proposed role of LAMA (tiotropium) in the asthma treatment in adults as add-on to the GINA 2014 recommen-
dations
Step Background treatment Rescue medications Other recommended  
interventions
First-line Alternative
1 No treatment Low-dose ICS SABA Treatment of concomitant 
diseases.
Patient education.
Inhalation technique control.
Avoidance of the risk factors of 
exacerbations.
Non-pharmacological interven-
tions (e.g. specific immunothe-
rapy).
2 Low-dose ICS Low-dose theophylline/LTRA
3 Low-dose ICS + LABA Medium- or high-dose ICS or 
low-dose ICS + LTRA/tiotropium
SABA or low-dose ICS 
+ formoterol in one 
inhaler4 Medium- or high-dose ICS + LABA 
+ tiotropium (possibly)
Medium- or high-dose ICS + 
LTRA/tiotropium
5 Add-on therapy (e.g. addition of 
anti-IgE, bronchial thermoplasty (?), 
sputum testing), referral to  
a specialist
Low-dose oral glucocorticostero-
ids for a short time
asthma and COPD [39]. Four hundred and seventy 
two patients were randomized to two groups. One 
group received conventional treatment to which 
tiotropium in a daily dose of 18 mcg, while the 
other group received conventional treatment with 
placebo. A significant improvement with respect 
to the primary endpoint, i.e. the area under the 
FEV1 curve from 0 to 6 hours (a difference of 
186 ± 24 ml in favor of tiotropium; p < 0.001) 
and the morning FEV1 values before treatment 
administration (a difference of 98 ± 23 ml in favor 
of tiotropium; p < 0.001), was observed. Benefits 
from the addition of tiotropium were also visible 
with respect to the FVC values before treatment 
administration (a difference of 128 ± 34 ml; 
p < 0.001) and the area under the FVC curve 
from 0 to 6 hours (a difference of 232 ± 35 ml; 
p < 0.001). In comparison with the situation 
before treatment initiation, the mean number 
of salbutamol doses per week was reduced by 
0.05 ± 0.12 doses per day in the placebo group 
and by 0.5 ± 0.12 doses per day in the tiotropium 
group in the 12th week of treatment (p < 0.05).
At present, tiotropium bromide (Spiriva Re-
spimat) is the only LAMA registered for treatment 
of patients with asthma. The characteristics of 
the Respimat inhaler may improve tiotropium 
availability and minimize the negative impact 
of incorrect inhalation technique on treatment 
effectiveness. Hochrainer et al. observed that the 
aerosol cloud produced by the Respimat inhaler 
lasts much longer (ca. 1.5 s) than that produced 
by CFC-MDI or HFA-MDI inhalers (0.2–0.4 s). In 
the same study, velocity of the aerosol produced 
by specific inhalers was also evaluated and the 
most favorable result (i.e.  the lowest velocity) 
was also that of Respimat (< 1 m/s at 10 cm from 
the mouthpiece). Moreover, the share of small 
particles (60–70%) in the aerosol cloud generated 
by Respimat is also favorable. In addition, in vitro 
studies demonstrated that Respimat generated 
lower flow resistance than dry powder inhalers 
(DPI) [40]. 
It should be remembered that the objective of 
introduction of tiotropium in clinical practice is 
not to replace ICS that must remain the mainstay 
of asthma treatment. The proposed role of LAMA 
in light of the current GINA recommendations is 
presented in Table 3.
The following patients groups should espe-
cially benefit from addition of tiotropium to their 
treatment:
—  those with the asthma/COPD overlap syndro-
me,
—  those with frequent exacerbations,
—  those with symptomatic asthma despite 
intensive pharmacological treatment (i.e. hi-
gh-dose ICS and LABA),
—  those with progressive deterioration of lung 
function,
—  those with progressive obstruction of the 
airways,
—  those with productive cough and neutrophils 
in the sputum,
—  current smokers,
—  those with a good effect of short-acting anti-
cholinergics used as rescue medication.
Effects of suboptimal asthma control, including 
economic aspects 
The care for patients with uncontrolled asth-
ma generates enormous costs for the healthcare 
systems in both developed and developing coun-
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tries. It has been demonstrated that treatment of 
asthma exacerbations significantly increases the 
planned and unplanned costs in comparison with 
controlled or partially controlled asthma [41]. 
The costs related to asthma treatment increase 
steadily; these include both direct (outpatient 
visits, hospitalizations, medications) and indirect 
costs (lost workdays, social services, etc). Study 
results indicate that the mean annual cost per 
patient increases while the level of disease control 
decreases [42]. Treatment of severe and uncon-
trolled asthma generates significant direct costs 
(pharmacotherapy, hospitalizations, and emer-
gency interventions). Moreover, indirect costs, 
i.e.  lost productivity and the necessity to pay 
welfares and disability pensions, should also be 
taken into account. Due to asthma exacerbations, 
many school and work days are lost; the situation 
is the best in Western Europe and the worst in 
Japan and Central and Eastern Europe [43]. In 
the TENOR study, the utilization of healthcare 
resources by patients in whom asthma remained 
symptomatic despite treatment was evaluated. 
It was confirmed that the lack of asthma control 
significantly increases the number of: lost work 
and school days, outpatient visits, and days spent 
at the hospital [44]. 
The quality of life of a patient with asthma in 
whom the optimal asthma control has not been 
achieved is worse in each domain, leading to sys-
tematic limitation of daily activities, and in certain 
cases to eventual disability. In addition, a patient 
with uncontrolled asthma is forced to use rescue 
medications more often, generating additional 
costs and increasing the risk of adverse effects. 
Poland is one of the few European countries 
in which the rate of hospitalizations due to asth-
ma has increased in the last years [45]. In a report 
by the Łazarski University (2014), titled “Allergic 
diseases — an analysis of financing of healthcare 
and social services”, current data regarding direct 
and indirect costs of bronchial asthma in Poland 
have been presented [46]. The analysis demon-
strated that the number of hospitalizations due 
to asthma increased in the years 2009–2013, from 
32,062 in 2010 to 36,020 in 2013. The increase of 
costs of hospitalization of patients with asthma 
incurred by the National Health Fund (NHF), 
i.e. by PLN 10 million in 3 years (2010–2013), 
was also significant. The cost of a single hospi-
talization due to asthma in 2013 was PLN 2397, 
with a median of 6 days spent in the hospital 
(data for the year 2012). Data concerning services 
provided by the Social Insurance Institution have 
also been published. In 2013, 67,700 medical 
certificates of temporal incapacity for work due to 
bronchial asthma were issued. The mean number 
of workdays lost due to the disease was 21.98 per 
patient with asthma. Incapacity for work benefits 
are also paid to patients with asthma — in 2012, 
16,000 Polish citizens received such benefits to 
the amount of PLN 157 million. In 2013, 240 new 
benefit decisions were related to asthma. In 2012, 
total costs related to incapacity for work benefits 
due to asthma, incurred by the Social Insurance 
Fund, the state budget, and employers, amounted 
to PLN 209 million.
Summary and recommendations  
of the expert group
Uncontrolled asthma is a serious health and 
social problem, leading eventually do respiratory 
disability, and generating high costs for the he-
althcare system.
In Poland, costs related to lost productivity 
and reduced daily activities of the patient are 
still not taken into account. In reimbursement 
decisions, indirect costs increasing the total costs 
of adequate care are also ignored. Reimbursement 
of new medications with rational treatment costs 
would increase the range of available treatment 
options and improve the chance of achievement 
of desired effects of treatment in patients with 
severe and uncontrolled asthma.
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